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Differential effects of calcium antagonist subclasses on markers
of nephropathy progression.
Background. Numerous studies suggest that the dihydropy-
ridine calcium antagonists (DCAs) and nondihydropyridine
calcium antagonists (NDCAs) have differential antiproteinuric
effects. Proteinuria reduction is a correlate of the progression
of renal disease. In an earlier systematic review, calcium an-
tagonists were shown as effective antihypertensive drugs, but
there was uncertainty about their renal benefits in patients with
proteinuria and renal insufficiency.
Methods. A systematic review was conducted to assess the
differential effects of DCAs and NDCAs on proteinuria in hy-
pertensive adults with proteinuria, with or without diabetes,
and to determine whether these differential effects translate
into altered progression of nephropathy. Studies included in
the review had to be randomized clinical trials with at least
6 months of treatment, include a DCA or NDCA treatment
arm, have one or more renal end points, and have been initi-
ated after 1986. Summary data were extracted from 28 studies
entered into two identical but separate databases, which were
compared and evaluated by independent reviewers. The effects
of each drug class on blood pressure (N = 1338) and proteinuria
(N = 510) were assessed.
Results. After adjusting for sample size, study length, and
baseline value, there were no statistically significant differences
in the ability of either class of calcium antagonist to decrease
blood pressure. The mean change in proteinuria was +2% for
DCAs and −30% for NDCAs (95% CI, 10% to 54%, P = 0.01).
Consistently greater reductions in proteinuria were associated
with the use of NDCAs compared with DCAs, despite no sig-
nificant differences in blood pressure reduction or presence of
diabetes.
Conclusion. This analysis supports (1) similar efficacy be-
tween subclasses of calcium antagonists to lower blood pressure,
and (2) greater reductions in proteinuria by NDCAs compared
to DCAs in the presence or absence of diabetes. Based on these
findings, NDCAs, alone or in combination with an angiotensin-
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converting enzyme (ACE) inhibitor or an angiotensin recep-
tor blocker (ARB), are suggested as preferred agents to lower
blood pressure in hypertensive patients with nephropathy asso-
ciated with proteinuria.
Over the past 20 years, while deaths attributed to hy-
pertensive vascular disease have declined in the United
States, the incidence of end-stage renal disease (ESRD)
associated with hypertension has increased [1]. More-
over, the presence of even early stage nephropathy is an
independent risk factor for development of cardiovascu-
lar events [2]. Therefore, slowing progression of kidney
disease is an important factor to consider when select-
ing antihypertensive medications for patients with kidney
disease and proteinuria.
Proteinuria is a sensitive and independent predictor
for the progression of nephropathy and cardiovascular
disease [3–8]. Several clinical studies have shown that
higher levels of proteinuria are associated with increased
progression of renal and cardiovascular disease and that
reductions in proteinuria are associated with a decrease
in the rate of renal function deterioration and cardio-
vascular events [4–7, 9]. As a result of this relationship,
proteinuria is frequently used as a surrogate end point
in clinical research studies assessing the effects of anti-
hypertensive agents on the progression of renal disease
[5].
Reductions in blood pressure have been associated
with decreases in both urine protein excretion and the
progression of nephropathy in patients with chronic
kidney disease [4, 8, 10–12]. Both the angiotensin-
converting enzyme (ACE) inhibitors and angiotensin re-
ceptor blockers (ARBs) have been shown to have these
effects [12–16]. However, the evidence for the renopro-
tective effects of calcium antagonists is more equivocal.
This is exemplified by the results of prospective random-
ized trials where, in spite of similar levels of blood pres-
sure, nephropathy progression was faster and proteinuria
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higher in the group randomized to a dihydropyridine
calcium antagonist (DCA) compared to a blocker of the
renin-angiotensin system (RAS) [12, 14, 16].
A number of studies have suggested that the di-
hydropyridine and nondihydropyridine subclasses of
calcium antagonists may have differential effects on pro-
teinuria and the progression of renal disease [11, 12,
16–19]. In an earlier systematic review by Kloke et al,
the authors concluded that calcium antagonists are ef-
fective antihypertensive drugs, but there was uncertainty
about the renal benefits of these medications in patients
with proteinuric renal disease and renal insufficiency [5].
In several studies, dihydropyridine calcium antagonists
(DCAs) were not shown to reduce proteinuria or slow
the progression of renal insufficiency [9, 11, 12, 18, 20–
36]. In a limited number of studies, data suggested that
nondihydropyridine calcium antagonists (NDCAs) may
provide beneficial effects on kidney function [19, 37–41].
However, data from an adequately powered clinical trial
are needed to reach a conclusion regarding the ability
of NDCAs to reduce proteinuria and slow nephropathy
progression.
The purpose of this systematic review was to evaluate
data from recent clinical studies to determine the differ-
ential effects of calcium antagonists on renal outcomes
as measured by changes in proteinuria. The primary ob-
jective was to assess whether DCAs and NDCAs have
differential effects on proteinuria in hypertensive adults
with or without diabetes.
METHODS
Data sources
Multiple sources were used to obtain published and un-
published data relevant to this systematic review. Com-
puterized databases, including MEDLINE, PubMed,
Internet Grateful Med, Library of the National Medi-
cal Society, Find Articles, and EMBASE, were searched
using key words and index terms to identify relevant
published articles (Table 1). The references from these
articles were reviewed to identify additional clinical tri-
als. In addition, governmental agencies, medical organi-
zations, thought leaders, and pharmaceutical companies
that manufacture a calcium antagonist were contacted to
identify additional studies, with either negative or pos-
itive outcomes that should be considered for inclusion
in the systematic review. It should be noted that no ad-
ditional substantive data beyond that of the published
literature was produced using these sources. All stud-
ies considered for this review were documented. From
the 139 abstracts screened, 47 full-text articles were re-
trieved, and 20% (28/139) were included in the review [9,
11, 12, 17–41]. Criteria for study selection are described
below.
Table 1. Key words and index terms used to identify articles for
inclusion in the review
Albumin Gallopamil
Albuminuria Glomerular filtration rate (GFR)
Angiotensin-converting enzyme Hemodialysis
(ACE) inhibitor
Angiotensin receptor blocker High blood pressure
(ARB) inhibitor
Calcium antagonist Microalbuminuria
Calcium-channel blocker Nephropathy
Chronic renal failure Nicardipine
Creatinine Nifedipine
Creatinine clearance Nimodipine
Diabetes Nisoldipine
Diabetic Nondihydropyridine (NDHP)
Dihydropyridine (DHP) Protein
Diltiazem Proteinuria
End-stage renal disease (ESRD) Renal
Felodipine Verapamil
Study selection
Summary data was obtained from 28 randomized, con-
trolled trials assessing the effects of calcium antagonists
on renal end points in hypertensive patients with and
without diabetes. In order to be included in the review,
studies had to be designed as a randomized clinical trial
with a duration of at least 6 months of treatment; had to
include a DCA or NDCA treatment arm; had to have 1 or
more renal end points (e.g., proteinuria, glomerular filtra-
tion rate [GFR], creatinine level, ESRD, or dialysis); and
had to have been initiated after 1986. This cut-off date was
chosen for two reasons. Prior to 1986, proteinuria was not
used as an end point in any controlled, randomized trials
of the effects calcium antagonists on renal function, and
after this date, a highly sensitive radioimmunoassay be-
came the most commonly used technique for measuring
urine protein [42]. Twenty-eight studies were included in
this systematic review. Twenty-one studies included DCA
treatment groups, six included NDCA treatment groups,
and 1 included both (Table 2). Five studies included treat-
ment arms with combination therapy of calcium antago-
nists and ACE inhibitors.
In the systematic review process, the validity or quality
of each study included in the review must be measured.
However, the authors recognized that this approach is
inherently subjective and has been the subject of some
controversy [43–45]. As a result, an assessment of the
methodologic quality of each study in this review was
completed by instituting strict selection criteria that were
specific to the design of the study. Because the selection
criteria were objective, a single individual assessed the
quality of each study. This individual was blinded to the
outcome of the study in order to minimize selection bias.
These criteria were employed to ensure inclusion only of
studies with high methodological quality with respect to
the study design. Studies that were relevant to the clinical
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goals of the review but did not meet the selection criteria
were excluded from further consideration.
Data extraction
Several individuals received training on the process of
abstracting data for the systematic review in order to min-
imize interextractor variability. Each individual received
training on how to use the electronic data collection form
and an equivalent term dictionary. These individuals were
divided into two teams that independently reviewed all
of the articles included in the systematic review. Each
team entered information into identical but separate elec-
tronic databases. In situations where data was not avail-
able from published sources, the corresponding author
was contacted whenever possible to obtain the missing
data. After the data were abstracted from the articles,
the data in the two databases were compared to identify
discrepancies.
A third team of independent reviewers evaluated each
discrepancy. The reviewers compared the disparate data
to the original article and made a final determination con-
cerning which data to accept. An audit log was maintained
of all changes to the database. The two original indepen-
dent databases were locked and archived for analysis of
interextractor variability. Interextractor agreement was
97%, whereas tertiary verification led to error-free rates
of 100% for primary data fields and 99% for the sec-
ondary data fields.
Study outcomes
The primary end point of this review was the per-
centage change in proteinuria from baseline in patients
treated with DCAs or NDCAs. Proteinuria is a widely
accepted surrogate end point for the progression of renal
disease in studies of antihypertensive agents. In addition,
proteinuria was expected to occur more frequently than
ESRD or other renal outcomes, providing higher statis-
tical power for analysis using this measure. Secondary
end points included effect of DCAs and NDCAs on end-
ing proteinuria values, systolic blood pressure, diastolic
blood pressure, and mean arterial pressure (MAP). Pro-
gression of nephropathy was defined as an increase in
proteinuria in spite of blood pressure reduction or wors-
ening of renal function relative to the comparator defined
as either an increase of greater than 50% in serum crea-
tinine or a 25% reduction in GFR, if measured.
Study characteristics
Summary-level data were extracted from published ar-
ticles for 28 randomized trials that assessed the effects
of calcium antagonists and other antihypertensive agents
on the progression of renal disease. The characteristics of
the patients evaluated in these studies were considered
to be sufficiently similar to justify pooling the data for an
aggregate analysis. With the exception of 15 patients in-
cluded in the study by Schnack et al [34], all patients were
hypertensive (blood pressure greater than 140/90 mm
Hg), and all patients had decreased renal function.
Statistical analysis
The studies included in the review followed different
protocols, requiring standardization of variable defini-
tions for the purpose of analysis. Measures of urine pro-
tein (excluding albumin) were recorded in mg/day. Based
on the accepted estimation that 40% of total urine protein
is albumin, urine albumin measurements were converted
to urine protein values by dividing by 0.4 [46]. MAP was
calculated by adding the systolic blood pressure reading
plus two times the diastolic blood pressure reading, di-
vided by three.
The SAS (SAS Institute, Inc., Cary, NC, USA) soft-
ware program was used for all statistical analyses. Clin-
ical and demographic characteristics of each treatment
group were summarized with means and standard devia-
tions (SD) or percentages and were presented for groups
treated with DCA or NDCA and with and without dia-
betes. In order to evaluate the treatment effects of the
calcium antagonists, studies that included combination
treatment arms were not used for the primary analysis.
Treatment groups were compared in terms of the per-
centage change from baseline values while adjusting for
sample size. The effect of treatment duration on protein-
uria could not be assessed without individual patient data,
and comparisons of end values were also adjusted for du-
ration of treatment. Both end points were evaluated with
analysis of covariance (ANCOVA) using each study as an
experimental unit. The assumptions of ANCOVA were
confirmed, and no interactions between the covariates
were found. In addition, ANCOVA techniques were used
to compare diabetic groups on proteinuria end points and
to compare the treatment groups on the blood pressure
end points. All P values were based on two-sided tests,
and significance was set at P < 0.05.
Summary tables were compiled from study data re-
ported for the 28 trials included in the review. As a re-
sult, the statistical methods used to analyze summary data
from these articles treated each study as an independent
observation unit in the analysis.
RESULTS
Blood pressure parameters were analyzed for 1338 pa-
tients from 22 studies. The baseline characteristics were
not significantly different between the 1338 patients in-
cluded in the analysis and the 235 patients excluded
because of missing values. Both classes of calcium an-
tagonists decreased mean systolic and diastolic blood
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Table 3. Effects of dihydropyridine calcium antagonists (DCAs) and nondihydropyridine calcium antagonists (NDCAs) (monotherapy) on blood
pressure parameters
Baseline End-of-study
systolic systolic
blood blood Change in Baseline End-of-study Change in Baseline End-of-study
pressure pressure systolic diastolic blood diastolic blood diastolic MAP MAP
Mean value value blood pressure pressure blood Value value Change in
(95% CI) Mm Hg mm Hga pressure %a value mm Hg value mm Hga pressure %a mm Hg mm Hga MAP %
DCA 160 139 −13 95 82 −13 116 101 −13
(153 to 167) (136 to 142) (−17 to −9) (91 to 99) (80 to 84) (−16 to −10) (112 to 120) (98 to 104) (−16 to −10)
NDCA 164 133 −18.5 99 81 −17 120 99 −17
(138 to 190) (126 TO 140) (−28 to −9) (88 to 110) (76 to 86) (−26 to −8) (113 to 127) (94 to 104) (−23 to −11)
Difference −4 6 5.5 −4 1 4 −4 2 4
(−31 to 23) (−2 TO 14) (−5 to 16) (−16 to 8) (−5 to 7) (−5 to 13) (−14 to 4) (−3 to 7) (−3 to 11)
P value NA 0.13 0.28 NA 0.75 0.4 NA .5 .35
MAP is mean arterial pressure.
aResults were adjusted for sample size, study length, and baseline values.
pressure (Table 3). After adjusting for sample size, study
length, and baseline value, there was no statistically sig-
nificant difference in blood pressure reduction between
the classes.
Twenty-three studies had both baseline and end-of-
study proteinuria levels documented. As a result, 510
patients contributed data for this analysis. The baseline
characteristics were not significantly different between
the 510 patients included in the analysis and the 1081
patients excluded because of missing values. The base-
line, end-of-study, and change in proteinuria values are
shown in Table 4. A 32% difference in proteinuria val-
ues was observed between the two subclasses. There was
+2% change in proteinuria for DCAs and −30% change
for NDCAs (95% CI, 10% to 54%, P < 0.01) (Fig. 1).
There were consistently greater reductions in proteinuria
associated with the use of NDCAs than with the use of
DCAs, despite no statistically significant differences in
blood pressure between the groups.
In order to assess the effect of reductions in blood pres-
sure on proteinuria levels with DCA or NDCA treatment,
an analysis was completed that adjusted for sample size,
study length, and change in systolic blood pressure. A
27% mean change in proteinuria was observed between
the two calcium antagonist subclasses. There was +1%
change in proteinuria for DCAs and −26% change for
NDCAs (95% CI, −8% to 63%, P = 0.16) (Table 5).
Although not statistically significant, these results sug-
gested that the trend demonstrating greater reductions
in proteinuria associated with the use of NDCAs com-
pared with DCAs persisted after adjusting for changes
in blood pressure. A possible explanation for the lack of
statistical significance for this analysis is that there were
fewer studies that documented both baseline and end-of-
study blood pressure and proteinuria values, resulting in
low statistical power.
A secondary analysis that included data for calcium an-
tagonists as monotherapy and in combination with ACE
inhibitors or ARBs showed the mean change in protein-
uria was 2% for DCAs and −39% for NDCAs (95% CI
for a 41% difference, 19% to 63%, P = 0.002) (Table 6).
These findings suggest that NDCAs alone or in combina-
tion with an ACE inhibitor or ARB produced significant
reductions in proteinuria, whereas DCAs did not demon-
strate an antiproteinuric effect.
As a result of this differential effect of DCAs and ND-
CAs on proteinuria, NDCAs were expected to reduce
the progression of renal disease whereas DCAs were
not. However, an analysis of this end point was inconclu-
sive because of the limited number of studies involving
NDCAs included in this review. In addition, this review
was performed using summary data rather than individ-
ual patient data, and the relationship between calcium
antagonists and renal disease progression could not be
fully assessed.
There were also no statistically significant differences
in proteinuria or blood pressure parameters in patients
with or without diabetes in any of the studies. As a result,
no further analysis of diabetic patients by treatment was
undertaken.
The sensitivity of the aggregate results was evaluated
by assessing the impact of each individual study on the
pooled results in order to determine whether the ob-
served effects of the DCAs and NDCAs were affected
by inclusion of any of the clinical trials. The analysis was
schematically repeated, excluding each study in turn, to
identify which studies were most influential on the re-
sults. Because only seven studies included a NDCA, it
was expected that the results would be somewhat sensi-
tive. However, the direction of the results and the mag-
nitude of the effects were expected to remain stable.
The sensitivity analysis revealed that the study by
Smith, Toto, and Bakris [17], when removed from the
analysis, was most influential in reducing the magnitude
of the treatment effect (+2% for DCAs and −26% for
NDCAs, P = 0.038) [17]. The study by Preston et al [39]
was the most influential in increasing the magnitude of the
treatment effect when removed from the analysis (+1%
Bakris et al: Effects of calcium antagonist subclasses on nephropathy progression 1997
Table 4. Effects of dihydropyridine calcium antagonists (DCAs) and dihydropyridine calcium antagonists (NDCAs) (monotherapy) on
proteinuria in patients with renal disease, by studya
Number Number Baseline End-of-study
(entire (sample of Study proteinuria proteinuria
population the population length value value Change
Study under study) under study) months mg/day mg/day %
DCAs
Abbott, Smith, and Bakris [18] 28 28 6 10313 10188 −1
Agodoa et al [11] 653 217 36 500 ND NA
Bianchi et al [20] 16 8 12 1688 ND NA
Bigazzi et ak [21] 40 20 24 163 132 −19
Chan et al [22] 102 52 66 190 224 18
Estacio et al [23] 470 235 60 ND ND NA
Ferder et al [9] 30 12 12 2840 2660 −6
Fogari et al [24] 38 19 6 1939 1743 −10
Herlitz et al [25] 158 54 22 913 ND NA
Kumagai et al [26] 28 16 12 1700 1500 −12
Lewis et al [12] 1715 567 30 ND ND NA
Marin et al [27] 67 40 36 2400 2900 21
Norgaard et al [28] 15 8 6 1995 2340 17
Okamura et al [29] 20 9 12 2000 2000 0
Petersen et al [30] 60 20 21 4325 5300 18
Romero et al [31] 20 10 6 3300 3800 15
Ruilope et al [32] 34 22 12 753 658 −13
Sawicki [33] 39 9 24 2500 4000 60
Schnack et al [34] 15 8 12 210 98 −54
Smith, Toto, and Bakris [17] 21 10 21 873 905 4
Velussi et al [35] 44 22 36 10705 10852 1
Zucchelli, Saccala, and Gaggi. [36] 121 61 36 1900 1500 −21
Total 3734 1447
Mean 170 66 23 2830 2988 2
NDCAs
Bakris, Barnhill, and Sadler [37] 30 8 12 5700 2900 −49
Bakris et al [19] 52 18 63 4500 2700 −40
Bakris et al [38] 37 11 12 1510 1053 −30
Preston et ak [39] 206 61 24 143 172 20
PROCOPA Study Group [41] 101 25 6 4730 4870 3
Slataper et ak [40] 30 10 18 7250 4000 −45
Smith, Toto, and Bakris [17] 21 11 21 908 389 −57
Total 477 144
Mean 68 21 22 3534 2298 −30
aMean adjusted for sample size and study length.
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Fig. 1. The change in proteinuria and systolic blood pressure. The per-
centage change in proteinuria, after adjustment for sample size and
study length, for dihydropyridine calcium antagonists (DCAs) and
nondihydropyridine calcium antagonists (NDCAs) was 2% and −30%,
respectively (P < 0.01). The percentage change in systolic blood pres-
sure, after adjustment for sample size and study length, for DCAs and
NDCAs was −13% and −18.5%, respectively (P = 0.28).
for DCAs and −36% for NDCAs, P = 0.004). All steps
in the sensitivity analysis showed a significant differential
effect on proteinuria between the DCAs and NDCAs. In
addition, the magnitude of the effect remained stable.
Therefore, the aggregate results of this review were not
sensitive to the inclusion or exclusion of any individual
study.
DISCUSSION
It has been established that calcium antagonists are
effective for reducing blood pressure in patients with re-
nal failure who are considered to be relatively resistant
to antihypertensive treatment [5]. This benefit is consis-
tent with the results from this review. According to this
analysis, both DCAs and NDCAs equally reduced blood
pressure. There were no significant differences in any of
the blood pressure parameters after treatment. This is fur-
ther supported by outcomes data from large trials such
as the Irbesartan Diabetic Nephropathy Trial (IDNT)
and the African American Study of Kidney Disease and
Hypertension (AASK) trials as well as other studies,
which show a strong association between reductions in
proteinuria and slower declines in kidney function [11,
12, 15, 16]. In the trials, a DCA (amlodipine) failed to
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Table 5. Estimated changes in proteinuria among patients treated with dihydropyridine calcium antagonists (DCAs) or nondihydropyridine
calcium antagonists (NDCAs) (monotherapy) adjusted for sample size, study length, and blood pressure parameters
Change in Change in Change in Change in Change in Change in
proteinuria proteinuria proteinuria roteinuria proteinuria proteinuria
adjusted for adjusted for adjusted for adjusted for adjusted for adjusted for
baseline baseline baseline change change change
systolic blood diastolic blood mean arterial systolic blood diastolic blood mean arterial
Mean (SE) pressure % pressure % pressure % pressure % pressure % pressure %
DCA 2 2 1.4 1.4 1.5 1.3
(6.9) (6.9) (6.3) (7.0) (7.0) (6.3)
NDCA −32 −31 −37 −26 −26 −36
(14.2) (14.4) (10.9) (16.9) (16.7) (10.9)
Difference 34 33 38.4 27.4 27.5 37.3
P value 0.05 0.06 0.009 0.16 0.15 0.009
Table 6. Effects of dihydropyridine calcium antagonists (DCAs) and nondihydropyridine calcium antagonists (NDCAs) [monotherapy or with
angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) on proteinuria in patients with renal disease, by studya
Number (entire Number (sample Study Baseline End-of-study
population of the population length proteinuria proteinuria Change
Study under study) under study) months value mg/day value mg/day %
DCAs
Abbott, Smith, and Bakris [18] 28 28 6 10313 10188 −1
Agodoa et al [11] 653 217 36 500 ND NA
Bianchi et al [20] 16 8 12 1688 ND NA
Bigazzi et al [21] 40 20 24 163 132 −19
Chan et al [22] 102 52 66 190 224 18
Estacio et al [23] 470 235 60 ND ND NA
Ferder et al [9] 30 12 12 2840 2660 −6
Fogari et al [24] 38 19 6 1939 1743 −10
Herlitz et al [25] 158 105 22 1113 ND NA
Kumagai et al [26] 28 16 12 1700 1500 −12
Lewis et al [12] 1715 567 30 ND ND NA
Marin et al [27] 67 40 36 2400 2900 21
Norgaard et al [28] 15 8 6 1995 2340 17
Okamura et al [29] 20 9 12 2000 2000 0
Petersen et al [30] 60 40 21 3763 4413 17
Romero et al [31] 20 10 6 3300 3800 15
Ruilope et al [32] 34 22 12 753 658 −13
Sawicki [33] 39 9 24 2500 4000 60
Schnack et al [34] 15 8 12 210 98 −54
Smith, Toto, and Bakris [17] 21 10 21 873 905 4
Velussi et al [35] 44 22 36 10705 10852 1
Zucchelli, Succala, and Gaggi [36] 121 61 36 1900 1500 −21
Total 3734 1518
Meana 170 69 23 2797 2936 2
NDCAs
Bakris, Barnhill, and Sadler [37] 30 16 12 6250 2300 −63
Bakris et al [19] 52 18 63 4500 2700 −40
Bakris et al [38] 37 25 12 1605 791 −51
Preston et al [39] 206 61 24 143 172 20
PROCOPA Study Group [41] 101 51 6 4439 3381 −24
Slataper [40] 30 10 18 7250 4000 −45
Smith, Toto, and Bakris [17] 21 11 21 908 389 −57
Total 477 192
Meana 68 27 22 3585 1962 −39
aMean adjusted for sample size and study length.
reduce proteinuria, an effect that correlated with a faster
decline in kidney function, despite substantial reductions
in blood pressure.
However, an analysis of the studies included in this re-
view suggested that a differential effect exists between
DCAs and NDCAs on proteinuria, despite equal reduc-
tions in systemic blood pressure. This analysis showed
that there were consistently greater reductions in pro-
teinuria with the use of NDCAs, either alone or in com-
bination with an ACE inhibitor or ARB, compared with
DCAs. This trend persisted after adjusting for changes in
blood pressure. This trend also remained unchanged for
both diabetic and nondiabetic renal disease and differing
levels of proteinuria.
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The differential effect of DCAs and NDCAs on pro-
teinuria has been studied in several animal models, and
in one human study [17, 47–49]. This differential effect
could be caused by a variety of factors, including differ-
ences in the ability of DCAs and NDCAs to affect re-
nal autoregulation, glomerular permeability, and tubular
protein reabsorption.
Results from animal studies suggested that DCAs,
through their action on the afferent arteriole, markedly
attenuate the autoregulatory ability of the kidney to alter
GFR over a wide range of arterial pressures. This would
result in linear transmission of the systemic blood pres-
sure to the glomerular capillary [47–49], and hence, an in-
crease in intraglomerular pressure, unless blood pressure
was markedly reduced to levels well below 120 mm Hg
[48]. Glomerular hypertension also results in increased
protein filtration, albuminuria, and endothelial damage,
leading to the release of soluble mediators that promote
replacement of normal kidney tissue by fibrosis [47–49].
As a result, the beneficial effects of blood pressure reduc-
tion seen with DCAs are overcome by the increased trans-
mission of pressure into the glomerulus due to sustained
afferent vasodilatation [5]. In experimental studies,
NDCAs also interfere with renal autoregulation, al-
though they do not totally ablate this process [48]. This
differential effect from DCAs may be related, in part, to
the effects of NDCAs on efferent as well as afferent arte-
riolar tone [50–52]. Additionally, NDCAs, unlike DCAs,
reduce glomerular permeability [9, 17, 25, 53]; this ef-
fect on permeability coupled with the partial preserva-
tion of renal autoregulation by NDCAs translate into
decreases in albuminuria and preservation of renal mor-
phology [47–49].
These differential effects on glomerular permeabil-
ity are also described in clinical studies, with one study
demonstrating a unique effect of DCAs to block tubular
protein reabsorption [17, 49, 54]. However, this would
only account for a small change in protein not albumin
and would not be unique to the DCAs. In human studies
of diabetic nephropathy, NDCAs were shown to reduce
glomerular membrane permeability, especially to large
molecules [17, 49]. This results in decreased albumin fil-
tration, proteinuria, and endothelial damage, that is as-
sociated with reduced progression of nephrosclerosis [55,
56]. These differences in membrane permeability are not
directly related to blood pressure lowering [17, 49].
Taken together, these mechanistic differences may ex-
plain the differential effect of DCAs and NDCAs on pro-
teinuria observed in this review. Further data from large
outcome trials is needed in humans to assess these hy-
pothesized explanations.
It is well documented that antihypertensive agents that
fail to reduce proteinuria in patients with nephropathy
also fail to maximally alter progression of renal disease
[8, 11, 16, 49, 57]. This suggests that reductions in both
blood pressure and proteinuria are necessary to reduce
nephropathy progression in patients with proteinuria [12,
58–61].
In two randomized, double-blind studies of patients
with advanced nephropathy and proteinuria, IDNT and
AASK, DCAs, in the absence of agents that block the
RAS, failed to reduce proteinuria levels and to slow
the progression of nephropathy, despite achieving reduc-
tions in blood pressure comparable to that achieved with
an ACE inhibitor or ARB. In contrast, controlled clini-
cal trials of NDCAs have consistently shown reductions
in both blood pressure and proteinuria, and the use of
NDCAs in participants with advanced diabetic nephropa-
thy have been shown to slow the progression of renal
disease in small studies with long-term follow-up [19,
37–41]. Based on the results of controlled clinical trials
that demonstrated an association between a reduction in
blood pressure and proteinuria and a slowing of the pro-
gression of renal disease, the results of this review support
the suggestion that NDCAs may be superior to DCAs in
reducing the progression of nephropathy.
Because DCAs have not demonstrated as beneficial as
blockers of the RAS on the progression of kidney disease,
they should not be considered a first-line treatment in
patients with kidney disease who have proteinuria. Con-
versely, NDCAs, alone or in combination with an ACE
inhibitor or an ARB, should be considered over DCAs
alone for treating hypertensive patients with nephropa-
thy and proteinuria. A recent post hoc analysis of the
Reduction of End Points in Type 2 Diabetes With the
Angiotensin II Antagonist Losartan (RENAAL) trial,
however, shows that DCAs when used with an ARB
do not abrogate the benefits of the ARB for slowing
nephropathy progression [57]. Further, because ESRD
and cardiovascular morbidity and mortality are clinically
important outcomes of renal disease progression, an anal-
ysis of these outcomes should be incorporated into future
comparative studies of the renoprotective effects of cal-
cium antagonists. Such studies will provide valuable in-
sight into the therapeutic advantages of using calcium
antagonists in conjunction with antihypertensives in the
treatment of renal disease.
The findings of this review have both clinical and
economic implications for health care providers. In a
recent cost analysis using United States Renal Data Ser-
vice (USRDS) data, costs associated with the treatment
of ESRD have been estimated at approximately $66,000
United States dollars per patient per year [62]. The world-
wide cost is estimated to be between $70 and $75 billion
United States dollars. The use of medications with re-
nal protective properties can significantly reduce health
care costs associated with renal disease. Herman et al re-
cently performed a cost analysis of the RENAAL study
and estimated that the ARB generated a net savings of
$3555 United States dollars per patient over 3.5 years in
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treatment costs for ESRD [63]. Therefore, antihyperten-
sive agents with documented renal protective properties
can improve clinical outcomes while reducing health care
costs.
Limitations of the study
A meta-analysis was originally planned in order to
more fully assess the differential effect of DCAs and
NDCAs on blood pressure, and proteinuria. In order to
assess these effects, all of the studies included in the meta-
analysis had to have included treatment arms with both
DCAs and NDCAs. However, only 1 study included in
the review met this criterion. As a result, a differential
effect between DCAs and NDCAs could not be assessed
with meta-analytical techniques. Instead, a systematic re-
view was conducted.
In addition, this review was performed using summary
data rather than individual patient data. As a result, the
unit of observation was the study and not the patient.
Therefore, the statistical power of the analysis was lower
than it would have been with an analysis of the individ-
ual patient data. The nonsignificant difference between
groups in terms of systolic and diastolic blood pressure
and MAP did not necessarily mean that groups were simi-
lar; a lack of data could also account for this lack of differ-
ence. However, even with the reduction in power caused
by using the study as the unit of analysis, there was com-
pelling evidence to support the findings that DCAs and
NDCAs differentially affect proteinuria while having no
significant difference in their effect on blood pressure.
CONCLUSION
This analysis supports the following conclusions: (1)
there was no statistically significant difference between
DCAs and NDCAs in their effect on blood pressure pa-
rameters; (2) NDCAs are superior to DCAs in reducing
proteinuria, despite no statistically significant difference
in the blood pressure–lowering effects of these two sub-
classes; and (3) the antiproteinuric superiority of NDCAs
was evident in both diabetic and nondiabetic renal dis-
ease. Based on the findings of this systematic review and
the fact that proteinuria levels correlate with higher risk
of kidney failure and cardiovascular events [8, 64–66].
NDCAs, alone or in combination with an ACE inhibitor
or an ARB, should be preferred over DCAs for treating
hypertensive patients with proteinuric renal disease or
renal insufficiency.
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